-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $35 Price Target

Benzinga·06/12/2026 14:07:32
Listen to the news
Wedbush analyst David Nierengarten reiterates Damora Therapeutics (NASDAQ:DMRA) with a Outperform and maintains $35 price target.